Beijing introduces 32 measures for innovative and high-quality development in the pharmaceutical industry

People’s Finance and Information April 8—Yesterday (the 7th), the “Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Pharmaceutical and Medical Technologies (2026)” was officially released. It aims to further accelerate innovation in Beijing’s pharmaceutical and healthcare industry, and to continuously build a full-chain support system spanning “R&D-approval-production-application,” providing innovative drug and device companies with precise, stable, and predictable policy conditions. It will comprehensively unleash the momentum for developing new quality productive forces. The “Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Pharmaceutical and Medical Technologies,” issued this time, includes 32 new initiatives. It will uphold the leading role of the Beijing (Beijing-Tianjin-Hebei) International Scientific and Technological Innovation Center, stay aligned with the forefront of pharmaceutical science and technology development, and plan for original innovation. Among them, regarding key steps such as drug technical review and marketing approval, Beijing’s market regulation authorities will step in early to provide consultation services and technical guidance. For drugs manufactured overseas and marketed in China, if there are major changes to the formulation prescription, production process, production site, quality standards, and other aspects, the market regulation authorities will optimize the review and approval process and improve the quality and efficiency of technical review and approvals, on the premise that procedures will not be reduced and standards will not be lowered. (CCTV News)